Business
Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago
Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nMeet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMeet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Oct. 26, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Oct. 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company Scientific Advisory Board Member, Dr. Yonina Tova (MD), an internationally recognized Radiation Oncologist, will be attending the American Society of Radiologic Technologists (ASRT) Radiation Therapy Conference (RTC) in Chicago on October 26, 2021. \nCompany Director and Head of Advisory Board, Dr. Gil Feiler, commented: \"Radiation therapy and chemoradiation therapy are part of the standard of care neoadjuvant treatments available for cancer patients. Our colorectal cancer treatment drug candidate RCC-33 could potentially improve the standard of care for neoadjuvant treatment by incorporating our cannabinoid-based neoadjuvant treatment into the standard of care. Parties interested in contacting or meeting with Cannabics Pharmaceuticals, and for more information on our colorectal cancer drug candidate RCC-33, please contact us at: [email protected]\".\nRead more:\nRecent expansion of Company's IP Portfolio with filing of 2 new Provisional Patents; Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.); Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler...